New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma
Evaxion A/S announced new data demonstrating its AI-Immunology platform's capability to identify novel endogenous retrovirus-derived antigens as targets for glioblastoma cancer vaccines. Collaborating with Duke University, the company found that integrating these ERV antigens could overcome challenges posed by glioblastoma's low mutational burden, …